• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Comparison of immunoadjuvant activities of four bursal peptides combined with H9N2 avian influenza virus vaccine

tetano

Editor, Senior Moderator
J Vet Sci. 2018 Aug 30. [Epub ahead of print]
[h=1]Comparison of immunoadjuvant activities of four bursal peptides combined with H9N2 avian influenza virus vaccine.[/h] Zhang C[SUP]1[/SUP], Zhou J[SUP]1[/SUP], Liu Z[SUP]1[/SUP], Liu Y[SUP]1[/SUP], Cai K[SUP]1[/SUP], Shen T[SUP]1[/SUP], Liao C[SUP]1[/SUP], Wang C[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The bursa of Fabricius (BF) is the central humoral immune organ unique to birds. The bursal peptide BPs (BP-I, BP-II, BP-III, BP-IV) were isolated and identified from BF. In this study, the immunoadjuvant activities of BP-(I-IV) were examined in mice immunized with H9N2 avian influenza virus (AIV) vaccines. The results suggested that BP-I effectively enhanced cell-mediated immune responses, increased the secretion of Th1 (gamma interferon [IFN-γ]) and Th2 (IL-4)-type cytokines, and induced a better cytotoxic T-lymphocyte (CTL) response to the H9N2 virus. BP-II mainly elevated specific-antibody production, especially neutralizing antibodies, and increased Th1- and Th2-type cytokines secretion. BP-III had no significant effect on antibody production and cell-mediated immune responses compared to the control group. A strong immune response at both the humoral and cellular levels was induced by BP-IV. Furthermore, a virus challenge experiment and HE staining revealed that BP-I and BP-II promoted removal of the virus and conferred protection in mice lungs. BP-IV significantly reduced viral titers and histopathological changes and contributed to protection against H9N2 AIV challenge in mice lungs. This study further researched the immunoadjuvant activities of BP-(I-IV) peptides, providing a novel insight on immunoadjuvant for vaccine design.


[h=4]KEYWORDS:[/h] BP-(I-IV); cellular immune response; humoral immune response; immunoadjuvant activities; immunoprotection

PMID: 30173497
 
Back
Top Bottom